$2995 | Single User
$4495 | Multi User
$8995 | Site License
$14995 | Global License

Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018
[Report Updated: 01-03-2018]

Published by Current Partnering: 01 Mar 2018 | 195808 | In Stock

Introduction

The Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 report provides details of the latest merger and acquisition (M&A) agreements announced in the pharmaceutical, biotechnology, diagnostic and other lifescience sectors. Fully revised and updated, the report provides details of M&A agreements from 2012 to 2018.


The report provides a detailed understanding and analysis of how and why companies enter M&A deals. The majority of deals are acquisitions whereby the acquirer acquires the target company in a cash and/or equity transaction.


Merger and acquisition is a constant activity within the biopharma sector. In the past, biopharma companies have sought to merge or acquire competitor companies in order to achieve critical mass both in R&D and sales and marketing, thus ensuring continued growth and dominance in a highly competitive and global marketplace.


In 1987, the largest ten companies were responsible for approximately twelve percent of global pharmaceutical sales. By 2002, this figure had become nearly fifty percent. This concentration was principally due to big pharma mega mergers.


The rewards offered for the successful marketing and sale of a block buster drug are enormous, therefore it is not surprising to see big pharma seeking ways of maximizing returns. Licensing has often been a means of achieving such global presence, but increasingly big pharma has sought to acquire its way into the major pharmaceutical markets. Until recently the mega merger was a popular means of growing presence globally; however the last few years have seen a concentration on smaller acquisitions to bolster R&D pipelines.


This report focuses on M&A between big pharma-big pharma, big pharma – smaller company, big biotech-big biotech, big biotech – smaller company, and smaller company-smaller company, providing a detailed insight into all such deals.


This report contains links to M&A deal records since 2012 including where availale online copies of actual merger and acquisition contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.


Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.


For example, analyzing actual company agreements allows assessment of the following:


What are the precise merger or acquisition terms agreed between the parties?


What is the plan of merger and how will it be implemented?


What is actually being acquired by the acquiring company?


What is the payment structure for the deal?


What are conditions of merger or acquisition?


What are the rights of shareholders and dissenters?


How are the key terms of the agreement defined?


How are IPRs handled and owned?


Who is responsible for what in the acquisition?


How is confidentiality and publicity managed?


Under what conditions can the deal be terminated?


Which boilerplate clauses does the company insist upon?


Which boilerplate clauses appear to differ from acquisition to acquisition?


Which jurisdiction does the company insist upon for agreement law?


The initial chapters of this report provide an orientation of M&A dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in M&A as well as a discussion on the merits of the type of deal.


Chapter 3 provides an overview of the structure of M&A deals. The chapter includes numerous case studies to enable understanding of M&A deals.


Chapter 4 provides a review of the leading M&A deals since 2012. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.


Chapter 5 provides a review of the top 50 most active biopharma companies in M&A. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.


Chapter 6 provides a comprehensive review of M&A financials for deals announced since 2012, including headline value, providing both benchmark data and access to individual deal financials.


Chapter 7 provides a comprehensive and detailed review of M&A deals signed and announced since 2012 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.


The report also includes numerous table and figures that illustrate the trends and activities in M&A deal making since 2012.


In addition, a comprehensive appendix is provided organized by M&A company A-Z, industry sector, therapeutic target, and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


In conclusion, this report provides everything a prospective dealmaker needs to know about M&A partnering in the research, development and commercialization of technologies and products.

Table of Contents
for Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 [Report Updated: 01-03-2018]

  • Executive Summary

    Chapter 1 – Introduction

    Chapter 2 – Trends in M&A dealmaking

    2.1. Introduction

    2.2. Difference between merger and acquisition deals

    2.3. Trends in M&A deals since 2012

    2.3.1. M&A dealmaking by year, 2012 to 2018

    2.3.2. M&A dealmaking by industry sector, 2012 to 2018

    2.3.3. M&A dealmaking by therapy area, 2012 to 2018

    2.3.4. M&A dealmaking by most active company, 2012 to 2018

    2.4. Key M&A trends

    2.5. Option to acquire the new acquisition?

    2.5.1. Case study 1: Cephalon – Ception

    2.5.2. Case study 2: HertArt Aps – Vitrolife

    2.6. When M&A can be useful

    2.7. Attributes of M&A deals

    2.7.1. M&A as an alternative to IPO

    2.8. Partnering deals with M&A component

    2.8.1. Partnering as a precursor to M&A

    2.8.1.a. Case study 3: Celgene – VentiRx Pharmaceuticals

    2.8.2. Equity as part of partnering deal

    2.8.2.a. Case study 4: BioMarin – Catalyst Pharma Partners

    2.8.2.b. Case study 5: Pfizer – Clovis Oncology

    2.8.2.c. Case study 6: Tesaro – OPKO Health

    2.8.3. Conversion of partnership to acquisition

    2.8.4. But M&A is not always the route followed

    2.9. Big pharma mega mergers – are we at the end of the road?

    2.9.1. Growth of Johnson & Johnson through M&A

    2.9.2. Growth of Novartis through M&A

    2.10. Accessing innovation through M&A

    2.10.1. Big pharma acquisitions of small companies

    2.10.1.a. Case study 7: Abbott – Facet Biotechnology

    2.10.1.b. Case study 8: Gilead Sceinces – Pharmasset

    2.10.2. Medium and small biopharma – use of M&A

    2.10.2.a. Case study 9: Allergan – MAP Pharmaceuticals

    2.10.2.b. Case study 10: Reckitt Benckiser – Schiff Nutrition International

    2.10.3. Using M&A to build a company

    2.10.3.a. Case study 11: Shire – built from M&A

    2.10.3.b. Case study 12: Zeneus - acquiring a ready-made European capability

    2.10.3.c. Case study 13: Novartis – from pure pharma to half generic

    2.10.4. Emergence of biotech-biotech mergers

    2.10.4.a. Case study 14: Merger between Biogen and Idec

    2.10.4.b. Case study 15: Amgen acquisition activity

    2.11. The emerging role of private equity in M&A

    2.12. Implementing M&A transactions

    2.13. Joint ventures as alternative to M&A

    2.14. The future of M&A in biopharma

    Chapter 3 – Overview of M&A deal structure

    3.1. Introduction

    3.2. Pure versus multi-component acquisition deals

    3.3. Pure M&A agreement structure

    3.3.1. Example acquisition agreements

    3.3.1.a. Case study 16: Allergan - SkinMedica

    3.4. Acquisition as part of a wider alliance agreement

    3.4.1. Example acquisition option clauses

    3.4.1.a. Case study 17: MGI Pharma – AkaRx

    3.5. Merger agreements

    3.5.1. Example merger agreements

    3.5.1.a. Case study 18: Synergy Pharmaceuticals – Callisto Pharmaceuticals

    Chapter 4 – Leading M&A deals

    4.1. Introduction

    4.2. Top M&A deals by value

    Chapter 5 – Top 50 most active M&A dealmakers

    5.1. Introduction

    5.2. Top 50 most active M&A dealmakers

    Chapter 6 – M&A contract directory 2012- 2018

    6.1. Introduction

    6.2. M&A deals with contracts 2012 to 2018

    Appendices

    Appendix 1 – M&A deals by company A-Z

    Appendix 2 – M&A deals by industry sector

    Appendix 3 – M&A deals by therapy area

    Appendix 4 –Deal type definitions

    About Wildwood Ventures

    Current Partnering

    Current Agreements

    Recent report titles from Current Partnering

    TABLE OF FIGURES

    Figure 1: Definition of merger and acquisition

    Figure 2: Trends in M&A deal announcements, 2012 to 2018

    Figure 3: MA& deals by industry sector, 2012 to 2018

    Figure 4: M&A deals by therapy area, 2012 to 2018

    Figure 5: Top 50 most active M&A dealmakers, 2012 to 2018

    Figure 6: Key recent M&A trends – 2012 to present

    Figure 7: Situations where M&A can prove useful

    Figure 8: Recent partnering deals involving equity participation in the licensor

    Figure 9: Equity investments converting to acquisitions

    Figure 10: Johnson & Johnson’s growth through M&A

    Figure 11: Novartis’s growth through M&A since 2000

    Figure 12: Shire’s M&A history

    Figure 13: Amgen’s biotech-biotech acquisition trail

    Figure 14: Recent private equity M&A activity

    Figure 15: Issues in implementing M&A agreements

    Figure 16: Recent joint venture agreements

    Figure 17: Recent joint ventures in the biopharma sector

    Figure 18: Future trends in M&A in biopharma

    Figure 19: Components of the acquisition deal structure

    Figure 20: Components of the merger deal structure

    Figure 21: Top M&A deals by value 2012 to 2018

    Figure 22: Most active M&A dealmakers 2012 to 2018

Additional Details

Publisher

Current Partnering

Publisher Information

Reference

195808 | CP2051

Number of Pages

1000

Report Format

PDF

Current Partnering Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017
The Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 ...
01 Nov 2017 by Current Partnering USD $2,995 More Info
Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017
The Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 ...
01 Oct 2017 by Current Partnering USD $2,995 More Info
Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017
The Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 ...
01 Sep 2017 by Current Partnering USD $2,995 More Info
Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017
The Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 ...
01 Apr 2017 by Current Partnering USD $2,995 More Info
Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017
The Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 ...
01 Feb 2017 by Current Partnering USD $2,995 More Info

This report is published by Current Partnering

Download Free Report Summary PDF

Global Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics 2012-2018 [Report Updated: 01-03-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)